|1.||Hewitt, J: 2 articles (06/2000 - 05/2000)|
|2.||Hsiang, Y N: 2 articles (06/2000 - 05/2000)|
|3.||Curtis, S B: 2 articles (06/2000 - 05/2000)|
|4.||Buchan, A M: 2 articles (06/2000 - 05/2000)|
|5.||Hong, Mun K: 1 article (12/2005)|
|6.||Chiu, Alex: 1 article (12/2005)|
|7.||Ng, William: 1 article (12/2005)|
|8.||Lam, Wai-Fat: 1 article (12/2005)|
|9.||Popma, Jeffrey J: 1 article (12/2005)|
|10.||Chow, Wing-Hing: 1 article (12/2005)|
08/01/1993 - "However, in the lower abdominal aorta, where balloon injury without local delivery was performed, there was a significant reduction of myointimal hyperplasia in the highest-concentration angiopeptin group (P < .001 versus the control group). "
08/01/1993 - "The feasibility and efficacy of a single dose of angiopeptin delivered locally via the Wolinsky porous balloon on myointimal hyperplasia were studied. "
07/01/1993 - "The study purpose was to determine if angiopeptin inhibits the development of intimal hyperplasia in normolipemic swine coronary arteries after overstretch-balloon injury. "
10/01/1993 - "These data suggest that treatment with angiopeptin may inhibit intimal hyperplasia in part by its beneficial effect on neoendothelial function."
08/01/1993 - "Angiopeptin can be delivered intramurally via the Wolinsky porous balloon and reduces myointimal hyperplasia only in the area distal to the local drug delivery site (downstream effect), possibly by healing the injured endothelium, by transport via the vasa vasora, and/or by systemic effect."
12/01/1995 - "Clinically, angiopeptin is safe in cardiac transplant patients and shows promise in inhibiting coronary transplant arteriosclerosis. "
01/01/1995 - "Effects of angiopeptin on transplant arteriosclerosis in the rat."
12/01/1995 - "Experimentally, angiopeptin inhibits transplant arteriosclerosis in cardiac, renal and vascular allografts. "
01/01/1995 - "We conclude that angiopeptin has no clear immunosuppressive properties but may counteract ischemia-induced transplant arteriosclerosis."
12/01/1995 - "Experimental transplant arteriosclerosis: inhibition by angiopeptin and low molecular weight heparin derivatives."
04/01/1993 - "Accelerated cardiac transplant atherosclerosis/chronic rejection in rabbits: inhibition by angiopeptin."
08/01/1989 - "Inhibition of coronary artery transplant atherosclerosis in rabbits with angiopeptin, an octapeptide."
12/01/1999 - "In this study of the inhibitory effects of angiopeptin and aspirin on the development of accelerated graft atherosclerosis (AGAS), 22 B10.BR mice received intra-abdominal heterotopic heart transplants from B10.A mice, without immunosuppression. "
05/01/1992 - "On the basis of the experimental data, clinical studies of the inhibitory effect of angiopeptin on prevention of transplant atherosclerosis in heart transplant patients and prevention of restenosis after coronary artery angioplasty are ongoing, as well as are studies in patients undergoing saphenous vein coronary artery bypass surgery."
12/01/1999 - "Effect of angiopeptin and aspirin on accelerated graft atherosclerosis in transplanted mouse heart."
|4.||Vascular System Injuries
06/01/1994 - "This speaks to the importance of early events immediately after vascular tissue injury, suggesting that angiopeptin inhibits the expression of early genes causally related to the vascular injury response and thereby triggering vascular cell proliferation."
05/01/1992 - "Further studies in simpler models of myointimal hyperplasia have shown that angiopeptin will inhibit smooth muscle cell proliferation after vascular injury. "
10/01/1996 - "Angiopeptin is an analog of somatostatin-14, which has been found to inhibit cellular proliferation in several models of systemic vascular injury. "
10/01/1993 - "Angiopeptin enhances acetylcholine-induced relaxation and inhibits intimal hyperplasia after vascular injury."
07/01/1993 - "Angiopeptin is an octapeptide analogue of somatostatin that has been shown to decrease the experimental intimal hyperplasia associated with vascular injury in rats and rabbits. "
12/01/1995 - "Furthermore, in large clinical trials, angiopeptin (given as a continuous infusion for 5 days) inhibits serious clinical events, such as myocardial infarction, death and revascularization at 6 and 12 months following percutaneous transluminal coronary angioplasty. "
11/11/1996 - "The 12-month event rate (death, myocardial infarction, coronary artery bypass grafting and re-PTCA) was reduced from 34% to 25% (p = 0.30) by angiopeptin by intention to treat analysis. "
07/01/1995 - "The hierarchical 12-month event rate (death, myocardial infarction, coronary artery bypass grafting, and repeated PTCA) was reduced from 34% to 25% (p = 0.30) by angiopeptin by intention-to-treat analysis. "
|2.||Aspirin (Acetylsalicylic Acid)
|3.||Somatostatin (Somatotropin Release-Inhibiting Factor)
|4.||Somatostatin Receptors (Somatostatin Receptor)
|7.||Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))
|10.||Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
|3.||Angioplasty (Angioplasty, Transluminal)
|4.||Coronary Balloon Angioplasty (Percutaneous Transluminal Coronary Angioplasty)
|5.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)